Life Sciences Genomics Discovery Platforms sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Genomics Discovery Platforms
1.1 - About Life Sciences Genomics Discovery Platforms sector
Companies in the Life Sciences Genomics Discovery Platforms category provide enterprise software and data solutions that ingest, analyze, and interpret large‑scale sequencing and multi‑omics datasets to accelerate target and biomarker discovery. These providers unify wet‑lab outputs with computational pipelines, apply AI to prioritize candidates, and enable reproducible, compliant workflows, helping pharma and biotech reduce discovery cycle times, improve decision quality, and de‑risk early R&D investments.
Offerings typically include NGS processing pipelines with scalable alignment, variant calling, and annotation; multi‑omics integration and normalization across genomics, transcriptomics, and proteomics; target identification and prioritization engines with pathway and network analysis; biomarker discovery and patient stratification modules; CRISPR and functional genomics screening analytics; AI/ML models for hit and lead optimization; and secure data management, collaboration APIs, and audit controls for regulated environments.
Primary customers include pharmaceutical R&D organizations, biotech discovery teams, and contract research partners supporting translational programs. These platforms enable faster target validation, higher hit‑finding rates, improved biomarker‑driven patient segmentation, and tighter data governance, while reducing analysis costs and shortening time to preclinical candidate selection. They help leaders make evidence‑based portfolio decisions and design studies aligned to genetic mechanisms of disease.
2. Buyers in the Life Sciences Genomics Discovery Platforms sector
2.1 Top strategic acquirers of Life Sciences Genomics Discovery Platforms companies
DNAnexus
HQ: United States
Website
- Description: Provider of a cloud-based precision health data platform and expert services that enable organizations to rapidly implement, manage, analyze and secure multi-omics and clinical data. DNAnexus delivers quick-start deployments, custom configuration, managed operations, solution accelerators, and training to maximize time-to-value, ROI and scientific insights.
- Key Products:
- Professional Services: Rapid implementation methodology configures DNAnexus from day one, taking clients live in weeks and tailoring the platform to unique scientific and regulatory requirements for faster ROI
- Managed Services: Post-implementation service that oversees ongoing platform configuration, administration and bioinformatics pipeline support, acting as an on-demand extension of customer teams
- Solution Accelerators: Catalog of pre-built solutions that enable multi-modal data integration
- AI/ML deployment, visualization and interactive exploration to speed insight generation on the DNAnexus platform
- Training & Support: DNAnexus Academy delivers personalized hands-on training, dedicated Customer Success advocates and on-demand Customer Care to ensure users gain skills and continuous value from the platform.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Life Sciences Genomics Discovery Platforms sector
M&A buyer group 1: Bioinformatics Platforms
3 companies
View group →
Description: Companies in this category deliver software platforms that ingest, manage, and analyze high-volume genomics and other omics datasets for research and clinical workflows. Life Sciences Bioinformatics Software vendors provide scalable pipelines, secure collaboration, and compliant data governance to accelerate discovery and diagnostics. For M&A analysts assessing strategic buyers in this space, these solutions unify sequencing data, automate analysis, and surface interpretable results for faster, reproducible insights.
Benchling
- Type: N/A
- Employees: ●●●●●
- Description: Provider of cloud-based scientific software for life science R&D that powers the Benchling R&D Cloud, enabling over 1,300 biotechnology companies to capture, manage, and analyze experimental data with modern tools, expert support, and a community of best practices.
- Key Products:
- Solution Accelerators: Pre-built Benchling configurations with data models, templates, dashboards and end-to-end workflows for cell and gene therapy, antibodies, etc., offering experimental tracking, sample management, and process modeling for up to 50% faster delivery and higher data consistency
- Benchling Learning Labs: Online, on-demand training platform where users and partners gain essential Benchling skills and certifications on R&D and administration tasks, boosting digital competencies in labs
- Success Packages: Comprehensive support bundles delivering product optimization, administration, and expert scientific and technical services to configure software and ensure high-quality outcomes for complex workflows
- Benchling R&D Cloud Platform: Unified cloud software that powers biotechnology research, digitizing laboratory processes and enabling data-driven, scalable, and efficient modern R&D operations.
🔒
🔒
🔒
View all 3 companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms in Life Sciences Genomics Discovery Platforms sector
3.1 - Buyout funds in the Life Sciences Genomics Discovery Platforms sector
2.2 - Strategic buyer groups for Life Sciences Genomics Discovery Platforms sector
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Life Sciences Genomics Discovery Platforms companies
4.2 - Public trading comparable groups for Life Sciences Genomics Discovery Platforms sector
Valuation benchmark group 1: Biologic Drug Discovery Tools Companies
3 companies
View group →
Description: Companies in this trading comparable group are public providers of biologics-focused discovery tools and platforms. They supply recombinant proteins, antibodies, assay reagents, and custom production plus AI-enabled design services that accelerate preclinical research and therapeutic development. They are grouped as comparables given shared catalog and services revenue models, overlapping pharma and research customers, and biotech tools margin profiles, offering consistent public trading comparables for valuation.
Vazyme Biotech
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of biotechnology solutions specializing in the design, manufacture, and application of bioactive proteins and compounds. The company focuses on innovative enzyme-based solutions for clinical and molecular diagnostics, among other applications.
- Key Products:
- COVID-19 Solution: Comprehensive assay and diagnostic solutions for COVID-19 testing, including qPCR kits and antibodies
- Molecular Biology Solutions: Offering reagents for PCR, qPCR, and NGS applications, catering to research and diagnostic needs
- Custom Oligos: Providing custom oligonucleotide synthesis services with a focus on high-performance and precision
- Enzyme Technologies: Development and manufacturing of enzyme solutions for diverse biological applications
- Reagent Kits: Producing high-quality reagent kits for DNA and RNA extraction and sequencing.
🔒
🔒
🔒
View all 3 companies in this group
Request Free Trial Now →
🔒
Revenue growth
Median
15.7%
2025E
16.0%
2026E
EBITDA margin
Median
28.2%
2025E
28.6%
2026E
Cash EBITDA margin
Median
27.6%
2025E
28.0%
2026E
EV/Revenue
Median
8.4x
2025E
6.8x
2026E
EV/EBITDA
Median
28.9x
2025E
24.4x
2026E
EV/Cash EBITDA
Median
29.0x
2025E
25.5x
2026E
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →